Enterprise Value
342.8M
Cash
210.1M
Avg Qtr Burn
-23.64M
Short % of Float
4.09%
Insider Ownership
6.59%
Institutional Own.
93.66%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
MAVYRET (Glecaprevir) Details HCV (Hepatitis C Virus) | Approved Quarterly sales | |
EDP-938 (N-inhibitor) Details Viral infection, Respiratory syncytial virus, Respiratory virus | Phase 2b Data readout | |
EDP-235 Details Viral infection, COVID-19 | Phase 2 Update | |
EDP-514 (HBV Core inhibitor) Details Hepatitis B | Phase 2 Initiation | |
EDP-323 Details Viral infection, Respiratory syncytial virus, Respiratory virus | Phase 1 Data readout | |
EDP-305 (FXR Agonist) Details Non-alcoholic steatohepatitis | Failed Discontinued | |
ENP-297 (FXR inhibitor) Details Non-alcoholic steatohepatitis | Failed Discontinued |